According to the Austrian Pharmacists Association in March, -- of -,--- pharmacies in Austria were not profitable in ---- despite revenues rising -.- in total to EUR-.--bn in the same year, as margins on prescription medication continued to contract (FriedlNews). In July ----, the European Investment Bank provided EUR--mn to Valneva, French-Austrian biotech company, which develops and markets vaccines for Lyme disease, Japanese encephalitis and Zika virus among others. The company s products are based on EB-- cell like, which according to the company is more effective in vaccine production than conventional egg-based platforms or other cell lines. Also in July ----, Valneva said that it has succeeded in generating a highly purified inactivated vaccine candidate against Zika virus using the same platform as the company s Japanese encephalitis vaccine which is marketed in the United States and Europe. Valneva indicated that clinical development could start in coming months depending on the outcome of the discussions with the regulatory authorities (Reuters). ...Also in July ----, Valneva said that it has succeeded in generating a highly purified inactivated vaccine candidate against Zika virus using the same platform as the company s Japanese encephalitis vaccine which is marketed in the United States and Europe. Valneva indicated that clinical development could start in coming months depending on the outcome of the discussions with the regulatory authorities (Reuters).
...BMI View: The Austrian pharmaceutical market, despite its small size in comparison with its EU-- partners, has one of the highest per capita expenditures globally due to its relatively small population, high burden of non-communicable diseases and ageing population. We believe pharmaceutical spending will post modest growth over the medium term as the government links growth in public healthcare expenditure with nominal GDP growth. ...BMI View: The Austrian pharmaceutical market, despite its small size in comparison with its EU-- partners, has one of the highest per capita expenditures globally due to its relatively small population, high burden of non-communicable diseases and ageing population. We believe pharmaceutical spending will post modest growth over the medium term as the government links growth in public healthcare expenditure with nominal GDP growth. Overall, we view the Austrian pharmaceutical and healthcare market as relatively stable and insulated from sudden downgrades. ...We believe pharmaceutical spending will post modest growth over the medium term as the government links growth in public healthcare expenditure with nominal GDP growth. Overall, we view the Austrian pharmaceutical and healthcare market as relatively stable and insulated from sudden downgrades.
...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...
...